- Cefpimizole
-
- $0.00 / 1kg
-
2025-05-30
- CAS:84880-03-5
- Min. Order: 1kg
- Purity: 0.99
- Supply Ability: 1000kg
|
| | Cefpimizole Basic information |
| Product Name: | Cefpimizole | | Synonyms: | Pyridinium, 1-[[(6R,7R)-2-carboxy-7-[[(2R)-[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, inner salt;Pyridinium, 1-[[2-carboxy-7-[[[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, inner salt, [6R-[6α,7β(R*)]]-;U 63196;(6R,7R)-7-[[(2R)-2-[(5-carboxy-1H-imidazole-4-carbonyl)amino]-2-phenylacetyl]amino]-8-oxo-3-[[4-(2-sulfonatoethyl)pyridin-1-ium-1-yl]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;CEFPIMIZOLE;1-[[(6R)-2-Carboxylato-7α-[[(R)-[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)pyridinium;Cefpimizol;cefpimizole:(6r,7r)-7-(((2r)-2-((5-carboxy-1h-IMIDAZOLE-4-carbonyl)amino)-2-phenylacetyl)amino)-8-oxo-3-((4-(2-sulfonatoethyl)pyridin-1-ium-1-yl)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxyli | | CAS: | 84880-03-5 | | MF: | C28H26N6O10S2 | | MW: | 670.67 | | EINECS: | | | Product Categories: | | | Mol File: | 84880-03-5.mol |  |
| | Cefpimizole Chemical Properties |
| | Cefpimizole Usage And Synthesis |
| Description | Cefpimizole sodium is a third-generation cephalosporin with a spectrum of activity
somewhat narrower than cefotaxime and cefoperazone. | | Originator | Ajinomoto (Japan) | | Uses | Antibacterial. | | Definition | ChEBI: Cefpimizole is a peptide. | | Brand name | Ajicef; Renilan | | Antimicrobial activity | A semisynthetic parenteral cephalosporin. It exhibits modest
activity compared to other antipseudomonal cephalosporins.
Like cefoperazone, it is susceptible to many enterobacterial
β-lactamases. In volunteers receiving 0.1–1 g intramuscularly,
mean peak plasma concentrations reached 15–20 and
35–40 mg/L, respectively. There was no accumulation when
the dose was repeated every 8 h for 7 days. No metabolites
have been detected. The plasma elimination half-life is 1.8–
2.1 h. The principal route of elimination is renal, 70–80%
being recovered unchanged in the urine.
Significant pain at the site of infection has been a prominent
adverse event. It is no longer widely available. |
| | Cefpimizole Preparation Products And Raw materials |
|